vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and JOINT Corp (JYNT). Click either name above to swap in a different company.
JOINT Corp is the larger business by last-quarter revenue ($15.2M vs $8.1M, roughly 1.9× Arcellx, Inc.). JOINT Corp runs the higher net margin — 6.5% vs -766.0%, a 772.6% gap on every dollar of revenue. On growth, JOINT Corp posted the faster year-over-year revenue change (3.1% vs -79.3%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-63.9M). Over the past eight quarters, Arcellx, Inc.'s revenue compounded faster (-24.6% CAGR vs -28.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
ACLX vs JYNT — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $15.2M |
| Net Profit | $-62.3M | $991.1K |
| Gross Margin | — | 81.4% |
| Operating Margin | -847.6% | 4.9% |
| Net Margin | -766.0% | 6.5% |
| Revenue YoY | -79.3% | 3.1% |
| Net Profit YoY | -765.1% | 5510.5% |
| EPS (diluted) | $-1.13 | $0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $13.4M | ||
| Q2 25 | — | $13.3M | ||
| Q1 25 | $8.1M | $13.1M | ||
| Q4 24 | $15.3M | $14.7M | ||
| Q3 24 | $26.0M | $30.2M | ||
| Q2 24 | $27.4M | $30.3M | ||
| Q1 24 | $39.3M | $29.7M |
| Q4 25 | — | $991.1K | ||
| Q3 25 | — | $855.0K | ||
| Q2 25 | — | $93.4K | ||
| Q1 25 | $-62.3M | $967.8K | ||
| Q4 24 | $-47.1M | $17.7K | ||
| Q3 24 | $-25.9M | $-3.2M | ||
| Q2 24 | $-27.2M | $-3.6M | ||
| Q1 24 | $-7.2M | $947.0K |
| Q4 25 | — | 81.4% | ||
| Q3 25 | — | 80.1% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 77.3% | ||
| Q4 24 | — | 78.4% | ||
| Q3 24 | — | 90.7% | ||
| Q2 24 | — | 90.7% | ||
| Q1 24 | — | 90.9% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | -8.6% | ||
| Q1 25 | -847.6% | -5.2% | ||
| Q4 24 | -348.2% | 5.5% | ||
| Q3 24 | -129.1% | -1.6% | ||
| Q2 24 | -127.8% | -5.9% | ||
| Q1 24 | -40.3% | -1.4% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | -766.0% | 7.4% | ||
| Q4 24 | -308.4% | 0.1% | ||
| Q3 24 | -99.4% | -10.5% | ||
| Q2 24 | -99.3% | -11.9% | ||
| Q1 24 | -18.3% | 3.2% |
| Q4 25 | — | $0.06 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | $-1.13 | $0.06 | ||
| Q4 24 | $-0.87 | $0.01 | ||
| Q3 24 | $-0.48 | $-0.21 | ||
| Q2 24 | $-0.51 | $-0.24 | ||
| Q1 24 | $-0.14 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $23.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $416.9M | $15.1M |
| Total Assets | $648.1M | $61.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $23.6M | ||
| Q3 25 | — | $29.7M | ||
| Q2 25 | — | $29.8M | ||
| Q1 25 | $543.3M | $21.9M | ||
| Q4 24 | $587.4M | $25.1M | ||
| Q3 24 | $574.3M | $20.7M | ||
| Q2 24 | $516.7M | $17.5M | ||
| Q1 24 | $573.9M | $18.7M |
| Q4 25 | — | $15.1M | ||
| Q3 25 | — | $22.7M | ||
| Q2 25 | — | $23.2M | ||
| Q1 25 | $416.9M | $22.8M | ||
| Q4 24 | $454.8M | $20.7M | ||
| Q3 24 | $483.0M | $20.5M | ||
| Q2 24 | $487.2M | $23.2M | ||
| Q1 24 | $496.6M | $26.2M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $73.2M | ||
| Q1 25 | $648.1M | $80.1M | ||
| Q4 24 | $711.3M | $83.2M | ||
| Q3 24 | $764.9M | $79.6M | ||
| Q2 24 | $734.3M | $82.4M | ||
| Q1 24 | $779.7M | $85.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $1.8M |
| Free Cash FlowOCF − Capex | $-63.9M | $334.7K |
| FCF MarginFCF / Revenue | -786.4% | 2.2% |
| Capex IntensityCapex / Revenue | 9.6% | 9.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | $-1.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $1.8M | ||
| Q2 25 | — | $868.6K | ||
| Q1 25 | $-63.1M | $-3.7M | ||
| Q4 24 | $-46.0M | $9.4M | ||
| Q3 24 | $30.7M | $3.4M | ||
| Q2 24 | $-36.2M | $-973.5K | ||
| Q1 24 | $-31.9M | $2.8M |
| Q4 25 | — | $334.7K | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $363.6K | ||
| Q1 25 | $-63.9M | $-4.0M | ||
| Q4 24 | $-47.5M | $8.2M | ||
| Q3 24 | $28.4M | $3.2M | ||
| Q2 24 | $-39.5M | $-1.2M | ||
| Q1 24 | $-38.3M | $2.4M |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 10.9% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | -786.4% | -30.8% | ||
| Q4 24 | -311.3% | 55.9% | ||
| Q3 24 | 109.2% | 10.6% | ||
| Q2 24 | -144.1% | -4.1% | ||
| Q1 24 | -97.7% | 8.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | — | 3.8% | ||
| Q1 25 | 9.6% | 2.5% | ||
| Q4 24 | 9.8% | 8.1% | ||
| Q3 24 | 8.8% | 0.8% | ||
| Q2 24 | 11.7% | 0.9% | ||
| Q1 24 | 16.4% | 1.3% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 2.07× | ||
| Q2 25 | — | 9.30× | ||
| Q1 25 | — | -3.82× | ||
| Q4 24 | — | 532.98× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACLX
Segment breakdown not available.
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
